Abstract
Background::
Systemic inflammatory regulators have been associated with preeclampsia (PE) during pregnancy; however, there is inconsistent evidence from animal models and observational results.
Methods::
Using summary data from genome-wide association studies (GWASs), we performed a bidirectional Mendelian randomization (MR) analysis of two samples of systemic inflammatory regulators (n = 8,186) and PE (n = 267,242) individuals of European ancestry. As our primary analysis, we used the random-effects inverse-variance weighted (IVW) approach. Sensitivity and pleiotropy analyses were conducted using the MR–Egger method, weighted median, MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO), and Cochran’s Q test.
Results::
The results indicate that there is a correlation between a higher circulating level of tumor necrosis factor alpha (TNF-α) and interleukin-9 (IL-9) and an increased risk of PE (odds ratio [OR] = 1.32, 95% confidence interval [CI] = 1.09–1.60, p = 0.004 and OR = 1.28, 95% CI: 1.02–1.62, p = 0.033, respectively). Conversely, lower levels of stem cell growth factor beta (SCGF-β) (OR = 0.89, 95% CI: 0.80–0.99, p = 0.027) and interleukin-5 (IL-5) (OR = 0.80, 95% CI: 0.65–0.98, p = 0.030) are linked to an increased risk of PE. The macrophage migration inhibitory factor (MIF) is the downstream inflammatory regulator of PE, according to reverse magnetic resonance imaging studies.
Conclusion::
Our study suggests that SCGF-β, IL-5, IL-9, and TNF-α causally affect the PE risk, while PE is causally associated with MIF. Further studies are needed to validate these biomarkers in managing PE.
Introduction
Background
Preeclampsia (PE) is a common and severe pregnancy complication, which is one of the leading causes of maternal mortality worldwide (). It is characterized by new-onset hypertension after 20 weeks of gestation and multiple organ dysfunction (). Women who survive PE may have a shorter life expectancy and an increased risk of stroke, cardiovascular disease, and diabetes (; ; ). However, the mechanism of this hypertensive disorder in pregnancy remains elusive. Increasing evidence shows that the balance between pro- and anti-inflammatory factors is an intrinsic mechanism of occurrence and development of PE.
Several studies have indicated the potential involvement of systemic inflammatory regulators in the development of PE. Various investigations have delved into the pathophysiological roles of cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17 (IL-17), interleukin-18 (IL-18), interferon gamma (IFN-γ), interleukin-4 (IL-4), and interleukin-10 (IL-10) in the progression of PE (; Yang et al., 2014; ). However, due to the presence of residual confounders, the conclusive establishment of a causal relationship between cytokines and PE remains elusive.
Mendelian randomization (MR) studies stand out as a distinctive and potent statistical approach to investigate causality between exposures (e.g., circulating cytokines) and outcomes (e.g., preeclampsia) of interest (Smith and Ebrahim, 2003; ). This method uses genetic instruments as unconfounded proxies for exposures, which can avoid residual confounding and reverse causality that is commonly present in conventional observational studies (). In the absence of randomized clinical trials (RCTs), MR design is an important strategy for causal inference as genetic variants are randomly assorted at meiosis, in which the procedure mimics an RCT (). Furthermore, a two-sample MR design using summary statistics from a genome-wide association study (GWAS) greatly increases the statistical power of causality inference (). Two-sample MR analysis allows researchers to evaluate the relationship between instrument exposure and instrument results in two separate population samples, thereby enhancing the applicability and effectiveness ().
Prior MR studies have investigated the causal influence of systemic inflammatory regulators on various diseases. Yeung et al. discovered that the considered systemic inflammatory regulators did not impact the risk of Alzheimer’s disease (AD). In contrast, specific cytokines such as interleukin-2 (IL-2), IFN-γ, TNF-α, and IL-18 might be downstream effects of AD (Yeung and Schooling, 2021). Song et al. (2022) demonstrated that elevated levels of IL-18 were correlated with a reduced risk of acute myeloid leukemia, while IL-17 was associated with the risk of stomach cancer. Wang et al. proposed that heightened levels of monocyte-specific chemokine-3 (MCP3), vascular endothelial growth factor (VEGF), IL-10, and IL-7 were linked to an increased risk of multiple myeloma (MM), whereas lower levels of tumor necrosis factor beta (TNF-β) were strongly associated with an elevated risk of MM (Wang et al., 2022).
Nevertheless, the bidirectional association between systemic inflammatory regulators and PE has not been explored to date. In this study, we employed a two-sample MR analysis to investigate the potential causal relationship between systemic inflammatory regulators and PE and vice versa.
Materials and methods
Study design
The summary data for the GWAS on systemic inflammatory regulators and PE were obtained from previously published studies (refer to Supplementary Table S1), obviating the need for additional ethical clearance. This study adheres to the STROBE-MR guidelines, as outlined by Skrivankova et al. (2021). The fulfillment of the three principal criteria is imperative, as delineated by VanderWeele et al. (2014) (): instrumental variables (IVs) exhibit a robust association with the exposure (); IVs are independent of any unidentified confounders existing between the exposure and outcome (); and IVs exclusively influence the outcome through their impact on the exposure.
Data sources and genetic associations.
Summary-level data for 41 systemic inflammatory regulators were acquired in this study from a GWAS, encompassing 8,293 individuals of Finnish descent from 3 distinct cohort studies: the Cardiovascular Risk in Young Finns Study, the FINRISK 1997 study, and the FINRISK 2002 study (). To ensure robust genetic associations, adjustments were made for age, sex, body mass index, and the top 10 genetic principal components.
The genetic association data pertaining to PE were sourced from a meta-analysis that included data from the UK Biobank, FinnGen, and BioBank. This meta-analysis involved 2,355 cases and 264,887 controls of European ancestry, as reported by Sakaue et al. (2021). Notably, this study represents a multi-country GWAS meta-analysis with minimal overlap with the GWAS on inflammatory regulators. Additionally, all single-nucleotide polymorphisms (SNPs) were derived from the analysis of European populations, thereby mitigating potential biases associated with population differences.
Selection of genetic instrumental variables
To mitigate the risk of false-positive IVs, we opted for statistically significant criteria (p < 5 × 10−6, linkage disequilibrium (LD) r2 < 0.001, and window size = 10,000 kb) in the summary data for systemic inflammatory regulators, as recommended by . Following the harmonization of the selected SNPs with those associated with PE, we identified a total of 41 circulating cytokines. To ensure the robustness of the instrumental variable, we verified that the F-statistics exceeded 10, adhering to the stringent mathematical formula: F = β2_exposure/SE2_exposure. The details of the 41 systemic inflammatory regulators chosen are provided in Supplementary Table S2.
For selecting IVs of PE, LD (r2 < 0.001) and proxies were tested for the 14 SNPs estimated to be correlated to PE at the genome-wide significance level (p < 5 × 10−6). Eventually, after harmonizing the exposure–outcome datasets, nine SNPs in total were included to construct the genetic IVs for PE (Supplementary Table S3).
Statistics
We systematically validated potential causal relationships between systemic inflammatory regulators and PE through a robust methodology. Primary MR analyses were conducted using the inverse-variance weighted (IVW) approach with random effects, utilizing genetic data to estimate causal effects between exposures and outcomes. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported, with statistical significance set at p < 0.05.
To enhance the reliability of our MR results, we implemented various heterogeneity and sensitivity assessments. Sensitivity analysis involved the utilization of the MR–Egger, weighted median, weighted mode, and simple mode techniques, as detailed by Xu et al. (2017). The MR–Egger method, employed to assess bias due to gene pleiotropic effects, demonstrated potential susceptibility and lower precision to a weak instrumental variable bias than other methods such as IVW and weighted median. The MR–Egger intercept was employed to identify horizontal pleiotropy, with statistical significance set at p < 0.05.
To further scrutinize pleiotropy and correct horizontal pleiotropy through outlier removal with potential pleiotropy, we employed MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO) as proposed by Verbanck et al. (2018). Cochran’s Q test was utilized to evaluate heterogeneity and horizontal pleiotropy. The analysis of Cochran’s Q test results and funnel plots served as indices to estimate individual SNP heterogeneity, in accordance with the approach outlined by ).
Additionally, we visually presented the results through scatter plots, forest plots, and leave-one-out plots, following the methodology described by Hemani et al. (2018). This comprehensive validation process strengthens the robustness and credibility of our findings regarding the causal relationships between systemic inflammatory regulators and PE. To account for multiple testing, we applied the Bonferroni method, which requires us to calculate associations with p-values below 0.0012 (0.05/41) as strong evidence of associations. The results with p-values ranging from 0.0012 to 0.05 were regarded as suggestive associations (Shi et al., 2023). Statistical analyses were performed and visualized using the R program (version 4.3.0) with the two-sample MR package (version 0.5.6) and MR-PRESSO (version 1.0) ().
Results
The causal effects of systemic inflammatory regulators on preeclampsia
The MR analysis uncovered a significant association between specific systemic inflammatory regulators—TNF-α, stem cell growth factor beta (SCGF-β), IL-9, and IL-5—and the risk of PE. All SNPs exhibited F-statistics greater than 10 (range 20.35–99.619; see Supplementary Table S2). Fourteen IVs were identified for SCGF-β, while IL-9, IL-5, and TNF-α had six, five, and five IVs, respectively. The IVW method demonstrated a significant difference (p < 0.05), and consistent directional effects were observed across five methods, namely, IVW, MR–Egger, weighted median, weighted mode, and simple mode (refer to Supplementary Table S4).
The IVW analysis revealed a negative association between SCGF-β (OR = 0.89, 95% CI: 0.80–0.99, p = 0.027) and IL-5 (OR = 0.80, 95% CI: 0.65–0.98, p = 0.030), indicating a decreased risk of PE. Although increased levels of interferon gamma-induced protein 10 (IP10) were associated with a reduced risk of PE, the IVW test results were inconclusive (p > 0.05), prompting the use of the MR–Egger method (OR = 0.66, 95% CI = 0.49–0.89, p = 0.026). The MR-Egger intercept did not indicate potential horizontal pleiotropy for SCGF-β and IL-5 (p = 0.968; p = 0.732, respectively), while IP10 exhibited pleiotropy (p = 0.033) (refer to Supplementary Tables S5, S6). Given that horizontal pleiotropy violates MR assumptions, the analysis involving IP10 was considered unreliable. Additionally, Cochran’s Q values based on the IVW tests showed no significant heterogeneity for SCGF-β and IL-5 (all p > 0.05; Supplementary Table S7).
Similarly, the IVW method revealed that elevated circulating levels of TNF-α and IL-9 were causally related to an increased risk of PE (OR = 1.32, 95% CI = 1.09–1.60, p = 0.004 and OR = 1.28, 95% CI: 1.02–1.62, p = 0.033, respectively). The MR–Egger intercept did not detect potential horizontal pleiotropy for TNF-α and IL-9 (p = 0.620 and p = 0.588, respectively). Cochran’s Q values based on the IVW tests indicated no significant heterogeneity for SCGF-β and IL-5 (all p > 0.05).
The MR results, along with heterogeneity analysis, pleiotropy analysis, and sensitivity analysis results, are summarized in Supplementary Tables S5–S7. No SNP significantly influenced the overall effect of cytokines on PE in the IVW leave-one-out sensitivity analysis. Supplementary Figures S1–S5 display scatter plots, funnel plots, forest plots, and leave-one-out plots, while Figure 1 presents the forest plots of the obtained results.
FIGURE 1
Furthermore, other systemic inflammatory regulators, including cutaneous T-cell-attracting chemokine, beta nerve growth factor, VEGF, macrophage migration inhibitory factor (MIF), TNF-related apoptosis-inducing ligand, TNF-β, MCP3, stromal cell-derived factor-1 alpha, stem cell factor, interleukin-12p70, interleukin-16, platelet-derived growth factor-BB, growth-regulated protein alpha, hepatocyte growth factor, interleukin-1 receptor antagonist, monocyte chemoattractant protein-1, macrophage inflammatory protein 1b, and IL-18, did not exhibit significant associations with PE in any of the analyses.
The causal effects of preeclampsia on systemic inflammatory regulators
Using nine SNPs as IVs for PE, we demonstrated that genetically predicted PE is negatively associated with MIF levels through the IVW method (OR = 0.87, 95% CI = 0.79–0.96, p = 0.007) (Supplementary Tables S8). All SNPs we selected had F-statistics greater than 10 (mean, 22.83; range, 20.97–27.69). The MR–Egger intercept did not detect potential horizontal pleiotropy (p = 0.705; Supplementary Tables S9). Cochran’s Q values based on the IVW tests showed that there was no obvious heterogeneity (p = 0.434). Detailed data are given in Supplementary Tables S10, S11. Figure 2 shows the forest plots of the above results. Scatter plots, funnel plots, forest plots, and leave-one-out plots are listed in Supplementary Tables S5.
FIGURE 2
Discussion
The goal of this extensive two-sample bidirectional MR investigation was to examine the causal relationship between systemic inflammatory regulators and PE by analyzing the large-scale summary GWAS data that are now available. It was discovered that none of these passed statistical significance after correction for multiple testing, although several suggestive results demonstrated biological plausibility. A higher risk of PE is linked to higher levels of TNF-α and IL-9 and lower levels of SCGF-β and IL-5. Genetically determined PE may also be a factor in a lower MIF level. This effect was further corroborated in a sensitivity analysis and was directionally consistent across various MR analyses.
There have been contradictory findings from earlier systematic reviews and meta-analyses of observational cohorts. They agreed with our results of TNF-α, IL-9, and IL-5 (6, 28, 29). Nonetheless, the contradictory findings were taken from observational research and combined. Reverse caution and confounding variables may skew the true causal links. Using a two-sample bidirectional MR analysis, we identified the inflammatory regulators of PE that are downstream (MIF) and upstream (TNF-α, IL-9, IL-5, and SCGF-β).
TNF-α is a multifunctional T-helper type 1 (Th1) cytokine and one of the most important inflammatory cytokines. TNF-α can induce structural and functional alterations in endothelial cells, enhancing the formation and release of endothelin and decreasing acetylcholine-induced vasodilating factors, such as nitric oxide (). A meta-analysis revealed that the maternal level of TNF-α was significantly higher in PE than that in the control group (mean difference = 8.11 pg/mL, 95% CI = 5.87–10.34 pg/mL) (; Spence et al., 2021). A report, therefore, proposed the use of etanercept for gestational hypertension (). Progesterone directly suppressed TNF-α-stimulated endothelin (ET)-1 and attenuated TNF-α-induced hypertension, possibly via the suppression of the renal ET-1 system (). Furthermore, dydrogesterone can cause a significantly reduced secretion of the Th1 cytokine TNF-α (). Anti-TNF-α appears to be a potential therapeutic approach for PE. The most common adverse pregnancy outcomes following the use of TNF-α inhibitors (e.g., etanercept) are intrauterine growth restriction, spontaneous abortion, and preterm birth (). So, how to balance the advantages and disadvantages of the drugs and which medications should be chosen at different trimesters of pregnancy have no consensus in clinical studies. SCGF-β is a hematopoietic growth factor that exerts its cellular activity at the early stage of hematopoiesis (Sukowati et al., 2018). No research focusing on the link between SCGF-β and PE has been identified thus far. Further investigation may be necessary to explore the potential use of SCGF-β as a biomarker for PE.
Additionally, IL-9, characterized as a T-cell growth factor and a member of the common γ-chain receptor cytokine family, originates from Th2 cells, Th9 cells, Th17 cells, Treg cells, mast cells, and natural killer cells (). IL-9 is implicated in maintaining pregnancy and laboring activity (; Sun et al., 2021). It has the potential to enhance the suppressive functions of Treg cells and the production of TGF-β by antigen-presenting cells, thereby preventing maternal immune activation against the fetus (). IL-9 accelerates the in vitro formation of trophoblastic capillary tubes, and first-trimester serum IL-9 levels differ significantly between preeclamptic and normotensive pregnant women (). In contrast to our findings, Sun et al. suggested that reduced IL-9 activity might lead to poorer angiogenesis and inadequate remodeling of the maternal uterine spiral arteries, potentially contributing to PE (Sun et al., 2020).
Regarding IL-5, previous studies have reported that IL-5, a Th2 cytokine, stimulates the proliferation, migration, and tube formation of human umbilical vein endothelial cells by activating the endothelial nitric oxide synthase pathway. Lower levels of IL-5 were observed across preeclamptic women in early pregnancy than that in normotensive women (Tangeras et al., 2015; ). This observational result aligns with our genetically based assumption. However, more clinical and animal studies are needed to elucidate the correlation between IL-5 and PE.
MIF promotes trophoblast migration, invasion, and remodeling spiral artery processes (; Vilotic et al., 2019). Abundant studies have described that placental soluble fms-like tyrosine kinase 1 (sFlt1) levels increase significantly in PE compared to normotensive pregnancy, while placental MIF positively correlates with sFlt1 expression (Yong et al., 2023). Reports on the comparison of serum MIF content between preeclamptic and normotensive pregnancies are controversial (Todros et al., 2005; ; ). No evidence shows that MIF is a downstream inflammatory regulator of PE so far. MIF measurement in PE might be of value, but additional research is needed to establish the reference range of serum MIF.
This study has several strengths. To the best of our knowledge, this is the first and most comprehensive MR study exploring the bidirectional relationship between 41 systemic inflammatory regulators and PE. Most studies investigating the link between systemic inflammatory regulators and PE relied on animal experiments and cross-sectional studies, precluding the ability to identify causality. We took the advantage of MR analysis to avoid reverse causal relations and minimize residual confounders. Furthermore, we used the latest version of systemic inflammatory regulators to conduct this MR study, making it the most up-to-date and comprehensive summary data in evaluating the causal relationship between systemic inflammatory regulators and PE. We restricted our study to women of European ancestry to avoid racial heterogeneity. Our study mainly focuses on both upstream and downstream circulating biomarkers that could depict the whole clinical picture in managing PE.
Nevertheless, there were some limitations. First, the large-scale GWAS data were summative, precluding further analysis at the individual-level data. The summary data for systemic inflammatory regulators encompassed both females and males, with gender differences excluding genetic variants on sex chromosomes (). It is important to note that this two-sample Mendelian randomization analysis was confined to the European population, and caution should be exercised in generalizing the conclusions to other ethnic groups due to genetic variations among different races (Tan et al., 2021). To comprehensively explore potential causality across races, efforts should be made to uncover more genetic information from diverse ethnic backgrounds.
Furthermore, it is worth acknowledging that MR may not be the optimal approach, considering that the exposure of interest can vary throughout life. However, the genetic instruments used in the analysis provide independent evidence from environmental or lifestyle factors, adding relevance to the study of PE.
In conclusion, we applied the bidirectional two-sample MR study to evaluate the causal effects of systemic inflammatory regulators on PE or vice versa. We then identified and validate the causal effect of IL-5, IL-9, TNF-α, and SCGF-β on PE. Conversely, MIF is a downstream inflammatory regulator of PE. Further efforts should be made to explore the precise contribution of systemic inflammatory regulators to the pathophysiology of PE. This will improve the management of PE in terms of early prediction, prevention, and treatment.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.
Ethics statement
Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and the institutional requirements.
Author contributions
CL: conceptualization, data curation, investigation, methodology, software, visualization, and writing–original draft. YT: conceptualization, data curation, formal analysis, investigation, methodology, and writing–original draft. DD: data curation, writing–original draft, data curation, and writing–original draft. LS: project administration, validation, visualization, and writing–review and editing. ZZ: funding acquisition, project administration, resources, and writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was co-supported by the National Science Foundation of China (No. 82071929) and Zhejiang Provincial Project for Education (No. Y202249319).
Acknowledgments
The authors thank Sakaue et al. for their contributions to the PE GWAS meta-analysis and Ahola-Olli et al. for the systemic inflammatory regulator GWAS meta-analysis.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2024.1359579/full#supplementary-material
References
1
Ahola-OlliA. V.WurtzP.HavulinnaA. S.AaltoK.PitkanenN.LehtimakiT.et al (2017). Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. Am. J. Hum. Genet.100 (1), 40–50. 10.1016/j.ajhg.2016.11.007
2
BowdenJ.SpillerW.Del GrecoM. F.SheehanN.ThompsonJ.MinelliC.et al (2018). Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. Int. J. Epidemiol.47 (4), 1264–1278. 10.1093/ije/dyy101
3
BrownM. A.MageeL. A.KennyL. C.KarumanchiS. A.McCarthyF. P.SaitoS.et al (2018). The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens.13, 291–310. 10.1016/j.preghy.2018.05.004
4
BurgessS.ButterworthA.ThompsonS. G. (2013). Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol.37 (7), 658–665. 10.1002/gepi.21758
5
CardaropoliS.IettaF.RomagnoliR.RolfoA.PaulesuL.TodrosT. (2014). Lower macrophage migration inhibitory factor concentrations in maternal serum before pre-eclampsia onset. J. Interferon Cytokine Res.34 (7), 537–542. 10.1089/jir.2013.0057
6
DaiF. F.HuM.ZhangY. W.ZhuR. H.ChenL. P.LiZ. D.et al (2022). TNF-α/anti-TNF-α drugs and its effect on pregnancy outcomes. Expert Rev. Mol. Med.24, e26. 10.1017/erm.2022.18
7
FuJ.LiL.QiL.ZhaoL. (2019). A randomized controlled trial of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders. Taiwan J. Obstet. Gynecol.58 (5), 621–625. 10.1016/j.tjog.2019.07.007
8
GuanX.FuY.LiuY.CuiM.ZhangC.ZhangQ.et al (2023). The role of inflammatory biomarkers in the development and progression of pre-eclampsia: a systematic review and meta-analysis. Front. Immunol.14, 1156039. 10.3389/fimmu.2023.1156039
9
HabbeddineM.VerbekeP.KarazS.BobeP.Kanellopoulos-LangevinC. (2014). Leukocyte population dynamics and detection of IL-9 as a major cytokine at the mouse fetal-maternal interface. PLoS One9 (9), e107267. 10.1371/journal.pone.0107267
10
HartwigF. P.DaviesN. M.HemaniG.Davey SmithG. (2016). Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int. J. Epidemiol.45 (6), 1717–1726. 10.1093/ije/dyx028
11
HemaniG.ZhengJ.ElsworthB.WadeK. H.HaberlandV.BairdD.et al (2018). The MR-Base platform supports systematic causal inference across the human phenome. Elife7, e34408. 10.7554/eLife.34408
12
HristoskovaS.HolzgreveW.ZhongX. Y.HahnS. (2006). Macrophage migration inhibition factor is elevated in pregnancy, but not to a greater extent in preeclampsia. Arch. Gynecol. Obstet.274 (1), 25–28. 10.1007/s00404-005-0109-8
13
IvesC. W.SinkeyR.RajapreyarI.TitaA. T. N.OparilS. (2020). Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review. J. Am. Coll. Cardiol.76 (14), 1690–1702. 10.1016/j.jacc.2020.08.014
14
JonssonY.MatthiesenL.BergG.ErnerudhJ.NieminenK.EkerfeltC. (2005). Indications of an altered immune balance in preeclampsia: a decrease in in vitro secretion of IL-5 and IL-10 from blood mononuclear cells and in blood basophil counts compared with normal pregnancy. J. Reprod. Immunol.66 (1), 69–84. 10.1016/j.jri.2005.02.002
15
Jovanovic KrivokucaM.StefanoskaI.Abu RabiT.Al-AbedY.Stosic-GrujicicS.VicovacL. (2015). Pharmacological inhibition of MIF interferes with trophoblast cell migration and invasiveness. Placenta36 (2), 150–159. 10.1016/j.placenta.2014.12.003
16
KeiserS. D.VeillonE. W.ParrishM. R.BennettW.CockrellK.FournierL.et al (2009). Effects of 17-hydroxyprogesterone on tumor necrosis factor-alpha-induced hypertension during pregnancy. Am. J. Hypertens.22 (10), 1120–1125. 10.1038/ajh.2009.149
17
KvalvikL. G.WilcoxA. J.SkjaervenR.OstbyeT.HarmonQ. E. (2020). Term complications and subsequent risk of preterm birth: registry based study. BMJ369, m1007. 10.1136/bmj.m1007
18
LaMarcaB. B.CockrellK.SullivanE.BennettW.GrangerJ. P. (2005). Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension46 (1), 82–86. 10.1161/01.HYP.0000169152.59854.36
19
LauS. Y.GuildS. J.BarrettC. J.ChenQ.McCowanL.JordanV.et al (2013). Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. Am. J. Reprod. Immunol.70 (5), 412–427. 10.1111/aji.12138
20
LawlorD. A.HarbordR. M.SterneJ. A.TimpsonN.Davey SmithG. (2008). Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med.27 (8), 1133–1163. 10.1002/sim.3034
21
LiuM.NiuY.MaK.LeungP. C. K.ChenZ. J.WeiD.et al (2023). Identification of novel first-trimester serum biomarkers for early prediction of preeclampsia. J. Transl. Med.21 (1), 634. 10.1186/s12967-023-04472-1
22
NoelleR. J.NowakE. C. (2010). Cellular sources and immune functions of interleukin-9. Nat. Rev. Immunol.10 (10), 683–687. 10.1038/nri2848
23
OngJ. S.MacGregorS. (2019). Implementing MR-PRESSO and GCTA-GSMR for pleiotropy assessment in Mendelian randomization studies from a practitioner's perspective. Genet. Epidemiol.43 (6), 609–616. 10.1002/gepi.22207
24
ParkS. L.ChungT. W.KimS.HwangB.KimJ. M.LeeH. M.et al (2017). HSP70-1 is required for interleukin-5-induced angiogenic responses through eNOS pathway. Sci. Rep.7, 44687. 10.1038/srep44687
25
PierceB. L.BurgessS. (2013). Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am. J. Epidemiol.178 (7), 1177–1184. 10.1093/aje/kwt084
26
PittaraT.VyridesA.LamnisosD.GiannakouK. (2021). Pre-eclampsia and long-term health outcomes for mother and infant: an umbrella review. BJOG128 (9), 1421–1430. 10.1111/1471-0528.16683
27
PoonL. C.ShennanA.HyettJ. A.KapurA.HadarE.DivakarH.et al (2019). The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int. J. Gynaecol. Obstet.145 (1), 1–33. 10.1002/ijgo.12802
28
RaghupathyR. (2013). Cytokines as key players in the pathophysiology of preeclampsia. Med. Princ. Pract.22, 8–19. 10.1159/000354200
29
RayesB.ArdissinoM.SlobE. A. W.PatelK. H. K.GirlingJ.NgF. S. (2023). Association of hypertensive disorders of pregnancy with future cardiovascular disease. JAMA Netw. Open6 (2), e230034. 10.1001/jamanetworkopen.2023.0034
30
SakaueS.KanaiM.TanigawaY.KarjalainenJ.KurkiM.KoshibaS.et al (2021). A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet.53 (10), 1415–1424. 10.1038/s41588-021-00931-x
31
ShiQ.WangQ.WangZ.LuJ.WangR. (2023). Systemic inflammatory regulators and proliferative diabetic retinopathy: a bidirectional Mendelian randomization study. Front. Immunol.14, 1088778. 10.3389/fimmu.2023.1088778
32
SkrivankovaV. W.RichmondR. C.WoolfB. A. R.YarmolinskyJ.DaviesN. M.SwansonS. A.et al (2021). Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA326 (16), 1614–1621. 10.1001/jama.2021.18236
33
SmithG. D.EbrahimS. (2003). 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?Int. J. Epidemiol.32 (1), 1–22. 10.1093/ije/dyg070
34
SongJ.LiA.QianY.LiuB.LvL.YeD.et al (2022). Genetically predicted circulating levels of cytokines and the risk of cancer. Front. Immunol.13, 886144. 10.3389/fimmu.2022.886144
35
SpenceT.AllsoppP. J.YeatesA. J.MulhernM. S.StrainJ. J.McSorleyE. M. (2021). Maternal serum cytokine concentrations in healthy pregnancy and preeclampsia. J. Pregnancy2021, 6649608. 10.1155/2021/6649608
36
SukowatiC. H. C.PattiR.PascutD.LadjuR. B.TarchiP.ZanottaN.et al (2018). Serum stem cell growth factor beta for the prediction of therapy response in hepatocellular carcinoma. Biomed. Res. Int.2018, 6435482. 10.1155/2018/6435482
37
SunY.LiuS.HuR.ZhouQ.LiX. (2020). Decreased placental IL9 and IL9R in preeclampsia impair trophoblast cell proliferation, invasion, and angiogenesis. Hypertens. Pregnancy39 (3), 228–235. 10.1080/10641955.2020.1754852
38
SunY.WuS.ZhouQ.LiX. (2021). Trophoblast-derived interleukin 9 mediates immune cell conversion and contributes to maternal-fetal tolerance. J. Reprod. Immunol.148, 103379. 10.1016/j.jri.2021.103379
39
TanJ. S.YanX. X.WuY.GaoX.XuX. Q.JiangX.et al (2021). Rare variants in MTHFR predispose to occurrence and recurrence of pulmonary embolism. Int. J. Cardiol.331, 236–242. 10.1016/j.ijcard.2021.01.073
40
TangerasL. H.AustdalM.SkrastadR. B.SalvesenK. A.AustgulenR.BathenT. F.et al (2015). Distinct first trimester cytokine profiles for gestational hypertension and preeclampsia. Arterioscler. Thromb. Vasc. Biol.35 (11), 2478–2485. 10.1161/ATVBAHA.115.305817
41
TodrosT.BontempoS.PiccoliE.IettaF.RomagnoliR.BiolcatiM.et al (2005). Increased levels of macrophage migration inhibitory factor (MIF) in preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol.123 (2), 162–166. 10.1016/j.ejogrb.2005.03.014
42
VanderWeeleT. J.Tchetgen TchetgenE. J.CornelisM.KraftP. (2014). Methodological challenges in mendelian randomization. Epidemiology25 (3), 427–435. 10.1097/EDE.0000000000000081
43
VerbanckM.ChenC. Y.NealeB.DoR. (2018). Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet.50 (5), 693–698. 10.1038/s41588-018-0099-7
44
ViloticA.Jovanovic KrivokucaM.StefanoskaI.Vrzic PetronijevicS.PetronijevicM.VicovacL. (2019). Macrophage migration inhibitory factor is involved in endovascular trophoblast cell function in vitro. EXCLI J.18, Doc1007. 10.17179/excli2019-1630
45
WangQ.ShiQ.LuJ.WangZ.HouJ. (2022). Causal relationships between inflammatory factors and multiple myeloma: a bidirectional Mendelian randomization study. Int. J. Cancer151 (10), 1750–1759. 10.1002/ijc.34214
46
XuL.BorgesM. C.HemaniG.LawlorD. A. (2017). The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian randomisation study. Diabetologia60 (11), 2210–2220. 10.1007/s00125-017-4396-y
47
YangY.SuX.XuW.ZhouR. (2014). Interleukin-18 and interferon gamma levels in preeclampsia: a systematic review and meta-analysis. Am. J. Reprod. Immunol.72 (5), 504–514. 10.1111/aji.12298
48
YeungC. H. C.SchoolingC. M. (2021). Systemic inflammatory regulators and risk of Alzheimer's disease: a bidirectional Mendelian-randomization study. Int. J. Epidemiol.50 (3), 829–840. 10.1093/ije/dyaa241
49
YongQ.DijkstraK. L.van der KeurC.BruijnJ. A.EikmansM.BaeldeH. J. (2023). MIF increases sFLT1 expression in early uncomplicated pregnancy and preeclampsia. Int. J. Mol. Sci.24 (12), 10050. 10.3390/ijms241210050
Summary
Keywords
cytokines, inflammation, preeclampsia, pregnancy, Mendelian randomization study
Citation
Li C, Tian Y, Dougarem D, Sun L and Zhong Z (2024) Systemic inflammatory regulators and preeclampsia: a two-sample bidirectional Mendelian randomization study. Front. Genet. 15:1359579. doi: 10.3389/fgene.2024.1359579
Received
09 January 2024
Accepted
08 March 2024
Published
22 March 2024
Volume
15 - 2024
Edited by
Phillip E. Melton, University of Tasmania, Australia
Reviewed by
Amir Ariff, University of New South Wales, Australia
Anca M. Panaitescu, Carol Davila University of Medicine and Pharmacy, Romania
Updates
Copyright
© 2024 Li, Tian, Dougarem, Sun and Zhong.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Litao Sun, litaosun1971@sina.com; Zixing Zhong, zhongzixing@hmc.edu.cn
‡ These authors have contributed equally to this work
ORCID: Zixing Zhong, orcid.org/0000-0002-2150-2419
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.